Related Experiment Videos

The phenomenon of multidrug resistance in non-Hodgkin's lymphoma

T P Miller¹, E M Chase, W S Dalton

¹Arizona Cancer Center, University of Arizona, Tucson 85724, USA.

Cancer Treatment and Research

|January 1, 1996

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016

The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Oncogene·2015

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

British journal of cancer·2014

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Leukemia·2013

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

See all related articles